Alendronate sodium in the management of osteoporosis.

Alendronate is one of the best and most extensively studied bisphosphonates in the treatment of osteoporosis. This review considers in detail the major pivotal study, the fracture intervention trial (FIT), upon which the use of alendronate is based and which was a landmark study in terms of design, size and clinical impact. The role of alendronate has subsequently been underscored by a range of studies extending the clinical indications for its use and consolidating the effect on reducing both vertebral and non-vertebral fracture risk. Although the emphasis of these studies has predominantly been on the management of postmenopausal osteoporosis, data is also available in primary prevention, men, and glucocorticoids-induced osteoporosis. Direct comparison between the different drugs used to treat osteoporosis with fracture end points are needed for patients and doctors to make informed choices, but the size of such studies are prohibitive. Clinical trials using surrogate markers such as bone mineral density and biochemical markers of bone turnover have been performed which provide some helpful information but the limitations of this approach need to be recognized.

A survey of laboratory practice in the clinical authorization and reporting of results.

BACKGROUND: The aim of this survey was to determine the practice of authorization and reporting of results in clinical biochemistry laboratories in the UK. METHOD: Questionnaires were distributed to the heads of clinical biochemistry departments through the National Audit Committee of the Association of Clinical Biochemists. The standards surveyed were based on guidelines for the reporting of results produced by the Royal College of Pathologists and the relevant Clinical Pathology Accreditation standards. RESULTS: Completed questionnaires were received from 137 laboratories. Workload ranged from 15,000 to 750,000 requests per annum (median 276,883). Most laboratories (98%) release results electronically to at least some wards in real-time. Areas where difficulties were identified included identifying requests that had posed specific questions and access to clinical information at the authorization stage, recording clinical advice given, and ensuring comments remained attached to printed reports or were on the same screen on computer reports. All but six laboratories had consultant advice available, including out of hours, but only 17% had an arrangement for clinical authorization to occur out of hours. CONCLUSION: Only 45 laboratories (33%) were able to achieve 100% compliance with the standards that currently exist, but many others showed evidence of good practice. The practical obstacles still to be overcome include limitations in the capabilities of laboratory computer systems, the lack of accessible electronic clinical records, the difficulties of covering work out of hours and insufficient appropriately trained staff.